NCT02254304View on ClinicalTrials.gov

Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™

PHASE4CompletedINTERVENTIONAL

Enrollment

106

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

August 20, 2016

Study Completion Date

August 20, 2016

Conditions

Relapsing Multiple SclerosisClinically Isolated Syndrome

Interventions

DRUG

Rebif

Rebif will be administered at a dose of 44 microgram (mcg) subcutaneously using RebiSmart auto-injector three times a week for a total duration up to 12 months.

Trial Locations (1)

Unknown

Please contact the Merck KGaA Communication Center, Darmstadt

All Listed Sponsors

collaborator

Merck Romania SRL, an affiliate of Merck KGaA, Darmstadt, Germany

UNKNOWN

lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT02254304 - Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™ | Biotech Hunter | Biotech Hunter